IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Maurice Winn who wrote (1605)	10/28/1998 2:57:00 AM
From: Webhead	Read Replies (1) of 1762

As I understand the new treatment protocol (which is spelled out in one of the recent annual reports) you need to clear the body of circulating lymphoma cells before you use the isotopic killing agent because you want the radioactive material to accumulate in TUMORS and not waft about the body attached to a lymphocyte causing more non-specific damage. First you treat with rituxan to get rid of circulating target cells. Then you add rituxan conjugated with radioactive indium in trace amounts and by measuring uptake into tumors an accurate dose of the yttrium conjugate is administered which should be rapidly taken up by the tumors. In this fashion you can deliver a strong theraputic dose of radiation at the site of the tumor while minimizing damage to other tissues (or at least that is the idea!). I didn't see mention of the indium compound so maybe IDEC has found a simpler way to judge the correct theraputic dose... Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next